Cilostazol

Generic Name: Cilostazol

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₇N_₅O_₂

CAS Number: 73963-72-1

Unique Ingredient Identifier: N7Z035406B

Background: Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both primary and secondary aggregation and reducing calcium-induced contractions.

Indication: Indicated for the alleviation of symptoms of intermittent claudication (pain in the legs that occurs with walking and disappears with rest).

Associated Conditions: Intermittent Claudication

Associated Therapies: -

Clinical Trials

A Mono-center Study in Healthy Volunteers on the Comparative Bioavailability of Pletal 100 mg Tablets and a New Pletal 100 mg Orodispersible Tablet (ODT), This Latter in Fasting Conditions With and Without Water and Under Fed Conditions

Phase 1

Completed

Conditions: Intermittent Claudication

Interventions: Drug: Cilostazol

First Posted Date: 2008-10-16

Last Posted Date: 2011-09-09

Lead Sponsor: Otsuka Frankfurt Research Institute GmbH

Target Recruit Count: 44

Registration Number: NCT00773630

Locations: 🇩🇪
AAIPharma Deutschland GmbH & Co. KG, Neu-Ulm, Germany

Cilostazol Stroke Prevention Study : A Placebo-controlled Double-blind Trial for Secondary Prevention of Cerebral Infarction.

Phase 3

Completed

Conditions: Cerebral Infarction

Interventions: Drug: placebo of cilostazol
Drug: cilostazol

First Posted Date: 2008-10-06

Last Posted Date: 2021-03-01

Lead Sponsor: Otsuka Pharmaceutical Co., Ltd.

Target Recruit Count: 1095

Registration Number: NCT00766545

Effect of Cilostazol in the Acute Lacunar Infarction Based on Pulsatility Index of Transcranial Doppler

Phase 4

Completed

Conditions: Cerebral Infarction

Interventions: Drug: cilostazol
Drug: Aspirin

First Posted Date: 2008-08-26

Last Posted Date: 2011-09-05

Lead Sponsor: Inje University

Target Recruit Count: 203

Registration Number: NCT00741286

Locations: 🇰🇷
Wonju Christian Hospital, Wonju, Korea, Republic of
🇰🇷
Sanbon Medical Center, Gunpo, Korea, Republic of
🇰🇷
Ajou University Hospital, Suwon, Korea, Republic of

and more 5 locations

Bioequivalency Study of 100 mg Cilostazol Tablets Under Fasting Conditions

Not Applicable

Completed

Conditions: Intermittent Claudication

First Posted Date: 2008-01-28

Last Posted Date: 2018-01-23

Lead Sponsor: Roxane Laboratories

Target Recruit Count: 32

Registration Number: NCT00602173

Locations: 🇺🇸
CEDRA Clinical Research, LLC, Austin, Texas, United States

Bioequivalency Study of 50 mg Cilostazol Tablets Under Fasting Conditions

Not Applicable

Completed

Conditions: Intermittent Claudication

First Posted Date: 2008-01-28

Last Posted Date: 2018-01-23

Lead Sponsor: Roxane Laboratories

Target Recruit Count: 36

Registration Number: NCT00602407

Locations: 🇺🇸
CEDRA Clinical Research, LLC, Austin, Texas, United States

Triple Versus Dual Antiplatelet Therapy After ABT578-Eluting Stent

Phase 4

Completed

Conditions: Coronary Artery Disease

Interventions: Drug: placebo
Drug: cilostazol

First Posted Date: 2008-01-10

Last Posted Date: 2010-03-18

Lead Sponsor: CardioVascular Research Foundation, Korea

Target Recruit Count: 486

Registration Number: NCT00589927

Locations: 🇰🇷
Seoul Veterans Hospital, Seoul, Korea, Republic of
🇰🇷
Ulsan University Hospital, Ulsan, Korea, Republic of
🇰🇷
Asan Medical Center, Seoul, Korea, Republic of

and more 7 locations

Effects of Cilostazol on Plasma Adipocytokine and Arterial Stiffness

Phase 4

Conditions: Diabetes Mellitus, Type 2
Metabolic Syndrome X

Interventions: Drug: Placebo
Drug: cilostazol

First Posted Date: 2007-12-14

Last Posted Date: 2007-12-14

Lead Sponsor: Korea University Anam Hospital

Target Recruit Count: 48

Registration Number: NCT00573950

Locations: 🇰🇷
Korea Univerisity Anam Hospital, Seoul, Korea, Republic of

Safety and Pharmacokinetics of Probucol and Cilostazol

Phase 4

Completed

Conditions: Healthy

Interventions: Drug: Probucol
Drug: Cilostazol

First Posted Date: 2007-10-26

Last Posted Date: 2022-03-04

Lead Sponsor: Korea Otsuka Pharmaceutical Co., Ltd.

Target Recruit Count: 32

Registration Number: NCT00549978

Locations: 🇰🇷
Clinical Trial Center, Seoul National University Hospital, Seoul, Korea, Republic of

Overcome Biochemical Aspirin Resistance Through Cilostazol Combination

Phase 4

Completed

Conditions: Cerebral Infarction

Interventions: Drug: placebo
Drug: Cilostazol

First Posted Date: 2007-03-13

Last Posted Date: 2010-01-18

Lead Sponsor: Asan Medical Center

Target Recruit Count: 244

Registration Number: NCT00446641

Locations: 🇰🇷
Jae-Kwan Cha, Busan, Korea, Republic of
🇰🇷
Kangdong Sacred Heart Hospital, Hallym University, Seoul, Korea, Republic of
🇰🇷
Eulji University Hospital, Daejon, Korea, Republic of

and more 1 locations

Efficacy and Safety of HMR1766 in Patients With Fontaine Stage II Peripheral Arterial Disease

Phase 2

Completed

Conditions: Intermittent Claudication

Interventions: Drug: placebo
Drug: ataciguat (HMR1766)
Drug: cilostazol

First Posted Date: 2007-03-05

Last Posted Date: 2018-05-17

Lead Sponsor: Sanofi

Target Recruit Count: 553

Registration Number: NCT00443287

Locations: 🇿🇦
Sanofi-Aventis Administrative Office, Midrand, South Africa

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy